[VCYT] Veracyte, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical Specialities

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 7.67 Change: 0.32 (4.35%)
Ext. hours: Change: 0 (0%)

chart VCYT

Refresh chart

Strongest Trends Summary For VCYT

VCYT is in the medium-term up 140% in 1 year. In the long-term up 277% above S&P in 1 year and up 349% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 29.28% Sales Growth - Q/Q-8.04% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-55.05% ROE-86.4% ROI
Current Ratio2.38 Quick Ratio2.12 Long Term Debt/Equity0.25 Debt Ratio0.4
Gross Margin58.11% Operating Margin-71.51% Net Profit Margin-72.28% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities90 K Cash From Investing Activities-440 K Cash From Operating Activities-8.87 M Gross Profit6.65 M
Net Profit-7.61 M Operating Profit-7.55 M Total Assets55.06 M Total Current Assets33.69 M
Total Current Liabilities14.15 M Total Debt4.95 M Total Liabilities19.98 M Total Revenue11.22 M
Technical Data
High 52 week26.41 Low 52 week6.19 Last close24.39 Last change-2.87%
RSI54.78 Average true range1.85 Beta1.25 Volume63.83 K
Simple moving average 20 days2.67% Simple moving average 50 days2.73% Simple moving average 200 days52%
Performance Data
Performance Week3.13% Performance Month6.37% Performance Quart31.13% Performance Half74.15%
Performance Year281.09% Performance Year-to-date93.88% Volatility daily4% Volatility weekly8.93%
Volatility monthly18.31% Volatility yearly63.42% Relative Volume207.13% Average Volume724.37 K
New High New Low

News

2019-06-17 08:30:00 | Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment

2019-06-14 14:59:58 | 7 Top-Rated Biotech Stocks to Invest In Today

2019-06-14 09:49:58 | GE wants to unload the portfolio of its Menlo Park venture arm

2019-06-10 16:15:00 | Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

2019-06-07 09:26:49 | Riskalyze hires Bay Area tech executive as CFO

2019-06-07 09:18:01 | New Strong Buy Stocks for June 7th

2019-06-01 14:15:00 | Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis

2019-05-30 12:49:41 | Before You Buy Veracyte, Inc. NASDAQ:VCYT, Consider Its Volatility

2019-05-29 16:20:00 | Veracyte Announces Participation in Two Upcoming Investor Conferences

2019-05-23 08:00:00 | Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting

2019-05-20 08:00:00 | Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis

2019-05-14 08:30:00 | Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology

2019-05-11 12:46:39 | Hedge Funds Have Never Been This Bullish On Veracyte Inc VCYT

2019-05-09 16:20:00 | Veracyte to Present at the UBS Global Healthcare Conference

2019-05-07 16:15:00 | Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-05-02 19:57:00 | Veracyte Announces Pricing of Public Offering of 5,500,000 Shares of Common Stock

2019-05-01 16:33:00 | Veracyte Announces Proposed Public Offering of Common Stock

2019-05-01 07:39:56 | The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

2019-05-01 06:56:48 | Edited Transcript of VCYT earnings conference call or presentation 30-Apr-19 9:00pm GMT

2019-04-30 22:44:24 | Veracyte VCYT Q1 2019 Earnings Call Transcript

2019-04-30 18:57:30 | Veracyte: 1Q Earnings Snapshot

2019-04-30 16:15:00 | Veracyte Announces First Quarter 2019 Financial Results

2019-04-30 15:00:00 | Veracyte, Inc. to Host Earnings Call

2019-04-23 10:32:02 | Will Veracyte VCYT Report Negative Earnings Next Week? What You Should Know

2019-04-23 08:08:52 | The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale

2019-04-22 16:15:00 | Veracyte Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State

2019-04-22 08:30:00 | Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development

2019-04-19 13:34:14 | Can You Imagine How Chuffed Veracyte's NASDAQ:VCYT Shareholders Feel About Its 297% Share Price Gain?

2019-04-09 15:33:39 | These Cannabis and China ETFs are Leading the 2019 Rally

2019-04-08 07:30:00 | Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype

2019-04-03 08:30:00 | Veracyte to Release First Quarter 2019 Financial Results on April 30, 2019

2019-04-01 18:46:00 | Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF

2019-03-28 16:15:00 | Veracyte Announces Participation in the 18th Annual Needham Healthcare Conference

2019-03-28 09:49:56 | 3 Small Biotech Stocks Hitting New Highs

2019-03-27 07:00:00 | Research Report Identifies Alamos Gold, Thermo Fisher Scientific, Veracyte, Air Lease, Carlisle Companies, and Medidata Solutions with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-03-25 16:15:00 | Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer

2019-03-22 09:36:01 | Will Veracyte Continue to Surge Higher?

2019-03-19 07:30:00 | Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition

2019-03-18 07:30:00 | Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019

2019-03-14 13:10:18 | Veracyte, Inc.’s NASDAQ:VCYT Shift From Loss To Profit

2019-03-14 11:15:03 | Veracyte VCYT Reports Q4 Loss, Tops Revenue Estimates

2019-03-05 10:53:03 | Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp

2019-03-04 08:30:00 | Veracyte Receives Final Medicare Coverage Policy for Envisia Genomic Classifier

2019-03-04 07:22:12 | 5 Stocks With Recent Price Strength to Maximize Your Gains

2019-02-26 23:45:14 | Edited Transcript of VCYT earnings conference call or presentation 25-Feb-19 10:00pm GMT

2019-02-26 13:52:55 | Veracyte Inc VCYT Q4 2018 Earnings Conference Call Transcript

2019-02-25 16:15:00 | Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook

2019-02-25 15:00:00 | Veracyte Inc to Host Earnings Call

2019-02-25 10:52:35 | Veracyte Q4 Earnings Preview

2019-02-20 16:20:00 | Veracyte Announces Participation in Upcoming Investor Conferences